{
    "2021-05-24": [
        [
            {
                "time": "",
                "original_text": "百克生物业绩增长的财技游戏",
                "features": {
                    "keywords": [
                        "百克生物",
                        "业绩增长",
                        "财技游戏"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物(300601)：国内疫苗创新先锋 丰富研发管线步入收获期",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "疫苗创新",
                        "研发管线",
                        "收获期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "大白马又被杀！3000亿猪茅闪崩跌停，东北药茅大跌",
                "features": {
                    "keywords": [
                        "大白马",
                        "猪茅",
                        "闪崩",
                        "跌停",
                        "东北药茅"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "农业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "国金证券：康泰生物（300601.SZ）国内疫苗创新先锋，目标价196元。给予“增持”评级",
                "features": {
                    "keywords": [
                        "国金证券",
                        "康泰生物",
                        "疫苗创新",
                        "目标价",
                        "增持"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物大跌 连续下跌",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "大跌",
                        "连续下跌"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "国金证券首予康泰生物增持评级：国内疫苗创新先锋，丰富研发管线步入收获期，目标价196元",
                "features": {
                    "keywords": [
                        "国金证券",
                        "康泰生物",
                        "疫苗创新",
                        "研发管线",
                        "收获期",
                        "目标价",
                        "增持"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "疫苗板块逆势下跌，康希诺闪崩大跌9%",
                "features": {
                    "keywords": [
                        "疫苗板块",
                        "逆势下跌",
                        "康希诺",
                        "闪崩",
                        "大跌"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药行业每周医览药闻：全年业绩确定性强 长期看好院外零售快速发展多元化发展",
                "features": {
                    "keywords": [
                        "医药行业",
                        "全年业绩",
                        "确定性",
                        "院外零售",
                        "快速发展",
                        "多元化发展"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物：20亿可转债提交注册，新增产能或存不能被及时消化风险",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "可转债",
                        "新增产能",
                        "风险"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}